Peptide Formulation Optimization

We refine peptide formulations based on the selected dosage form by precisely adjusting the type and amount of excipients to enhance stability, bioavailability, and drug release profiles. For oral peptides, for example, we may incorporate enzyme inhibitors or absorption enhancers to improve gastrointestinal stability and uptake. In transdermal applications, we fine-tune the type and concentration of penetration enhancers to boost skin absorption efficiency.

Our team optimizes peptide formulation manufacturing processes to increase efficiency, enhance product quality, and ensure batch-to-batch consistency. For instance, in lyophilized peptide injectables, we carefully control the lyophilization cycle—adjusting parameters like freezing rate, drying temperature, and vacuum pressure—to achieve optimal appearance, moisture content, and reconstitution behavior. In peptide microsphere production, we optimize emulsification parameters and polymer ratios to ensure consistent particle size distribution and high encapsulation efficiency.

We conduct comprehensive studies on factors affecting peptide stability—such as temperature, humidity, light exposure, and oxygen—and implement tailored strategies to address them. These may include the use of antioxidants, light-protective packaging, or optimized storage conditions. For peptides sensitive to moisture, we design moisture-resistant packaging and adapt manufacturing methods to enhance stability across various environmental conditions.

For transdermal patches and related dosage forms, we enhance film-forming systems to improve uniformity, flexibility, and adhesion. We ensure compatibility between the film matrix and the peptide, maintaining release profiles and bioactivity for effective skin-based delivery.

We increase peptide bioavailability by modifying dosage forms, optimizing routes of administration, and employing advanced formulation technologies. For oral peptides, we use techniques like nanotechnology and microencapsulation to protect against enzymatic and acidic degradation, improving absorption. For nasal delivery, we optimize formulation and design to extend mucosal residence time and increase absorption efficiency.

To improve in vivo stability and reduce degradation, we apply chemical modifications such as N-terminal acetylation and C-terminal amidation. Modifying enzyme-sensitive regions can dramatically extend peptide half-life.

Additionally, we select protective excipients—such as antioxidants (e.g., vitamin C, sulfites) to prevent oxidative degradation and lyoprotectants (e.g., sucrose, trehalose) to maintain peptide structure during freeze-drying and storage.

We develop advanced delivery systems to promote peptide absorption. For oral delivery, encapsulation in liposomes or nanoparticles protects peptides in the GI tract and facilitates mucosal absorption.

We also specialize in mucosal delivery platforms like nasal sprays and sublingual tablets. For nasal formulations, we adjust molecular weight and charge to improve mucosal adherence and systemic uptake.

We engineer sustained-release systems—such as peptide-loaded microspheres using biodegradable polymers like PLGA—to provide extended drug release over days or weeks. This reduces dosing frequency and improves patient compliance.

We also develop long-acting injectables by controlling interactions between peptides and carriers to modulate release rates. Gel-based systems, for instance, can form depots at the injection site, ensuring slow, sustained peptide diffusion.

To enhance therapeutic precision, we design targeting strategies by conjugating peptides with ligands such as antibody fragments or cytokines. These ligands bind selectively to receptors overexpressed on diseased cells, enabling localized drug delivery and minimizing systemic side effects—for example, using folic acid-conjugated peptides to target tumors with high folate receptor expression.

We also create smart delivery systems responsive to physiological cues, such as pH- or temperature-sensitive carriers. These systems release peptides in response to tumor-specific microenvironments, boosting local drug concentration and therapeutic impact.

In addition to conventional injection and oral routes, we explore alternative delivery methods. For transdermal delivery, we develop patch formulations using technologies like nanoemulsions or electrospun membranes to facilitate skin penetration and bypass first-pass metabolism.

We also design inhalation-based delivery systems—including dry powder inhalers and nebulized formulations—for peptides targeting the lungs, such as bronchodilators. These systems ensure efficient pulmonary delivery and are ideal for respiratory conditions.